COVID-19 redux: clinical, virologic, and immunologic evaluation of clinical rebound after nirmatrelvir/ritonavir

Clinical rebound of COVID-19 after nirmatrelvir/ritonavir treatment has been reported. We performed clinical, virologic, and immune measurements in seven patients with symptomatic rebound, six after nirmatrelvir/ritonavir treatment and one without previous treatment. There was no evidence of severe...

Descripción completa

Detalles Bibliográficos
Autores principales: Epling, Brian P., Rocco, Joseph M., Boswell, Kristin L., Laidlaw, Elizabeth, Galindo, Frances, Kellogg, Anela, Das, Sanchita, Roder, Allison, Ghedin, Elodie, Kreitman, Allie, Dewar, Robin L., Kelly, Sophie E. M., Kalish, Heather, Rehman, Tauseef, Highbarger, Jeroen, Rupert, Adam, Kocher, Gregory, Holbrook, Michael R., Lisco, Andrea, Manion, Maura, Koup, Richard A., Sereti, Irini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9216730/
https://www.ncbi.nlm.nih.gov/pubmed/35734093
http://dx.doi.org/10.1101/2022.06.16.22276392

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9216730/
https://www.ncbi.nlm.nih.gov/pubmed/35734093
http://dx.doi.org/10.1101/2022.06.16.22276392

Ejemplares similares